GE-HEALTHCARE
1.3.2023 08:01:54 CET | Business Wire | Press release
GE HealthCare has today announced, at the European Congress of Radiology (ECR) in Vienna, Austria, the completion of Phase I subject recruitment in its early clinical development program for a first-of-its-kind manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. Typically, MRI agents – used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue – are gadolinium-based. This manganese-based agent could broaden GE HealthCare’s portfolio of MRI contrast agents available to radiologists, providing a potential alternative in light of perceived concerns relating to gadolinium retention.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228006355/en/
GE HealthCare is innovating in contrast media (Photo: Business Wire)
The macrocyclic, extra-cellular – or general-purpose – manganese-based contrast agent has comparable relaxivity - the ability of a contrast agent to enhance signal intensity during an MRI scan - and is expected to be diagnostically similar to current gadolinium-based contrast agents (GBCAs). Unlike gadolinium, manganese is endogenous, meaning that it is a trace element that is naturally occurring in and efficiently eliminated from the body. Along with its magnetic properties, this makes a manganese-based agent a viable alternative to gadolinium. In addition, a non-gadolinium agent could help limit the potential impact of post-patient excreted gadolinium in the environment.
The clinical trial, based at the clinical research unit at the Oslo University Hospital, Rikshospitalet, Norway, and overseen by Lead Investigator, Hasse K. Zaré, aims to investigate the safety profile and how this injectable manganese contrast agent is eliminated from the body in healthy volunteers. Previous manganese-based MRI agents have been reliant on a ‘free manganese’ release mechanism for their imaging efficacy. This novel investigational agent is tightly bound to the chelate, in a macrocyclic cage-like structure, so it is rapidly eliminated from - rather than actively released into - the body.
Dr Paul Evans, Head of Global R&D at GE HealthCare’s Pharmaceutical Diagnostics unit, said: “For many years we’ve been committed to investing in, and bringing to market, products to help solve some of radiology’s biggest challenges and unmet needs. This manganese-based MRI agent is one of a number of novel agents we have at various stages of development in our innovation pipeline, all of which aim to give practitioners more choice in delivering precision care for their patients.”
GE HealthCare’s Pharmaceutical Diagnostics unit is a global leader in imaging agents used to support around 100 million procedures per year globally, equivalent to three patient procedures every second. For more than 40 years, GE imaging agents have been routinely used across MRI, X-ray/CT and ultrasound to enhance clinical images and support diagnosis.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 100 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $18.3 billion business with 50,000 employees working to create a world where healthcare has no limits.
Follow us on Facebook, LinkedIn, Twitter, and Insights for the latest news, or visit our website www.gehealthcare.com for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228006355/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor10.11.2026 19:14:00 CET | Press release
PIMJETMI is a new once-daily oral systemic treatment option for certain U.S. patients with symptomatic tenosynovial giant cell tumor (TGCT)In the Phase 3 MANEUVER trial, PIMJETMI demonstrated early1 and durable2 tumor response with clinically meaningful improvements in all clinical outcome assessments, including physical function and painPIMJETMI has shown high objective response rate (ORR) with a manageable safety profileNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has approved PIMJETMI® (pimicotinib), a once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor, as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. “People living with TGCT have long faced difficult treatment decisions as they navigate a disease that can significant
Smartsheet Integrates With Claude Sheets, Making It Easy to Start Projects in Claude and Launch Workflows Across Teams with Smartsheet10.11.2026 18:57:00 CET | Press release
New Send to Smartsheet feature moves work started in Claude into Smartsheet, where the Execution Graph connects it to the people, plans and goals that see it through Smartsheet, the AI-powered enterprise work management platform, today announced a new integration with Claude Sheets, the new spreadsheet artifact in Claude from Anthropic, now in beta. With the new Send to Smartsheet feature, people who build a tracker or plan in Claude can move it into Smartsheet in a few clicks. There they can put it to work with their team, connected to the plans, projects, people and systems their organization already runs on. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110763156/en/ With the new Send to Smartsheet feature, people who build a tracker or plan in Claude can move it into Smartsheet in a few clicks. More and more work now begins in a conversation with Claude, and the Smartsheet MCP connector for Claude puts the entire pow
InterSystems Joins Google Cloud as Launch Partner for Gemini for Healthcare10.11.2026 18:00:00 CET | Press release
Integration with InterSystems IRIS FHIR MCP will help healthcare organizations securely connect Gemini to trusted, standards-based health data InterSystems, a creative data technology provider powering more than one billion health records globally, today announced that it will serve as a launch partner for Google Cloud’s Gemini for healthcare. Through the collaboration, Gemini for healthcare will connect to the InterSystems IRIS FHIR Model Context Protocol (MCP) server, enabling healthcare organizations to give AI assistants and agents governed access to FHIR data. The integration will bring together Google Cloud’s Gemini capabilities and the standards-based data access provided by InterSystems IRIS FHIR MCP. InterSystems FHIR MCP serves the open Model Context Protocol directly from a FHIR endpoint, allowing MCP-enabled clients to discover and use FHIR tools for searching, reading, creating, updating, and managing healthcare data. “Healthcare organizations are looking for practical way
Coherent Solutions Launches AKTIV, a Dedicated Fitness and Wellness Technology Business Unit10.11.2026 16:34:00 CET | Press release
Coherent Solutions officially launches AKTIV, a dedicated business unit focused exclusively on fitness and wellness technology. AKTIV brings together over 15 years of fitness industry experience, dedicated leadership, and global engineering capabilities to help fitness and wellness operators and equipment manufacturers compete through technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110242555/en/ Coherent Solutions officially launches AKTIV “We know the fitness and wellness industry and the challenges operators and manufacturers face. With AKTIV, we spend less time defining what needs to be built and more time delivering solutions that improve operations, member experiences, and business performance,” said Vadim Bartlov, Managing Director of AKTIV. AKTIV builds on Coherent Solutions' established work with leading fitness companies, including Life Time, Planet Fitness, Anytime Fitness, Orangetheory, and BowFlex,
Mouser Explores the Newest Computing Technologies Beyond Moore's Law in its Technology Series10.11.2026 16:12:00 CET | Press release
Mouser Electronics, Inc., the authorized global distributor with the newest electronic components and industrial automation products, today announced the latest installment of its Empowering Innovation Together (EIT) technology series, Moving Beyond Moore's Law. The series explores how engineers are advancing computing performance as traditional semiconductor scaling approaches its physical limits, from chiplets and advanced packaging to silicon photonics and emerging transistor technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261006980414/en/ Explore what comes after Moore's Law as the industry seeks new paths to computing performance. As a key driver of semiconductor advancement, Moore's Law has served as a roadmap for the industry, describing the trend of transistor counts on integrated circuits doubling approximately every two years. With conventional silicon transistors becoming increasingly difficult to shr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom